---
document_datetime: 2025-12-29 11:58:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-zentiva.html
document_name: duloxetine-zentiva.html
version: success
processing_time: 0.1323302
conversion_datetime: 2025-12-30 10:46:13.157618
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Duloxetine Zentiva

[RSS](/en/individual-human-medicine.xml/66517)

##### Authorised

This medicine is authorised for use in the European Union

duloxetine Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Duloxetine Zentiva](#news-on)
- [More information on Duloxetine Zentiva](#more-information-on-duloxetine-zentiva-1350)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Duloxetine Zentiva. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Duloxetine Zentiva.

For practical information about using Duloxetine Zentiva, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Duloxetine Zentiva and what is it used for?

Duloxetine Zentiva is used to treat adults with the following diseases:

- major depression;
- pain due to diabetic peripheral neuropathy (damage to the nerves in the feet, legs, hands and arms that can occur in patients with diabetes);
- generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).

Duloxetine Zentiva contains the active substance duloxetine and is is a 'generic medicine'. This means that Duloxetine Zentiva is similar to a 'reference medicine' already authorised in the European Union (EU) called Cymbalta.

## How is Duloxetine Zentiva used?

Duloxetine Zentiva is available as gastroresistant capsules (30 and 60 mg). 'Gastroresistant' means that the capsules' contents pass through the stomach without being broken down until they reach the intestine. This prevents the active substance being destroyed by the acid in the stomach. The medicine can only be obtained with a prescription.

For major depression, the recommended dose of Duloxetine Zentiva is 60 mg once a day. A response is usually seen in two to four weeks. In patients who respond to Duloxetine Zentiva, treatment should continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past.

For diabetic neuropathic pain, the recommended dose is 60 mg per day but some patients may need a higher dose of up to 120 mg per day. The response to treatment should be assessed regularly.

For generalised anxiety disorder, the recommended starting dose is 30 mg once a day, but the dose can be increased to 60, 90 or 120 mg depending on the patient's response. Most patients will need to take 60 mg per day. Patients who also have major depression should start with 60 mg once a day. In patients who respond to Duloxetine Zentiva, treatment should continue for several months, to prevent the disorder coming back.

The dose of Duloxetine Zentiva should be reduced gradually when stopping treatment.

## How does Duloxetine Zentiva work?

The active substance in this medicine, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor. It works by preventing the neurotransmitters serotonin (5-hydroxytryptamine) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.

Neurotransmitters are chemicals that allow nerve cells to communicate with one another. By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between nerve cells, increasing the level of communication between the cells. Since these neurotransmitters are involved in maintaining mood and reducing the sensation of pain, blocking their re-uptake into nerve cells can improve the symptoms of depression, anxiety and neuropathic pain.

## How has Duloxetine Zentiva been studied?

Because Duloxetine Zentiva is a generic medicine of Cymbalta, its benefits and risks are taken as being the same as the reference medicine's.

## What are the benefits and risks of Duloxetine Zentiva?

Because Duloxetine Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Duloxetine Zentiva approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Duloxetine Zentiva has been shown to have comparable quality to Cymbalta and to be bioequivalent to Cymbalta. Therefore, the CHMP's view was that, as for Cymbalta, the benefit outweighs the identified risk. The Committee recommended that Duloxetine Zentiva be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Duloxetine Zentiva?

A risk management plan has been developed to ensure that Duloxetine Zentiva is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Duloxetine Zentiva, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the [Duloxetine Zentiva : EPAR - Risk-management-plan summary](/en/documents/rmp-summary/duloxetine-zentiva-epar-risk-management-plan-summary_en.pdf) .

## Other information about Duloxetine Zentiva

The European Commission granted a marketing authorisation valid throughout the European Union for Duloxetine Zentiva on 20 August 2015.

For more information about treatment with Duloxetine Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Duloxetine Zentiva : EPAR - Summary for the public

Reference Number: EMA/434593/2015

English (EN) (187.98 KB - PDF)

**First published:** 27/08/2015

**Last updated:** 27/08/2015

[View](/en/documents/overview/duloxetine-zentiva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-842)

български (BG) (132.91 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/bg/documents/overview/duloxetine-zentiva-epar-summary-public_bg.pdf)

español (ES) (109.91 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/es/documents/overview/duloxetine-zentiva-epar-summary-public_es.pdf)

čeština (CS) (130.9 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/cs/documents/overview/duloxetine-zentiva-epar-summary-public_cs.pdf)

dansk (DA) (109.16 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/da/documents/overview/duloxetine-zentiva-epar-summary-public_da.pdf)

Deutsch (DE) (110.07 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/de/documents/overview/duloxetine-zentiva-epar-summary-public_de.pdf)

eesti keel (ET) (108.42 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/et/documents/overview/duloxetine-zentiva-epar-summary-public_et.pdf)

ελληνικά (EL) (135.79 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/el/documents/overview/duloxetine-zentiva-epar-summary-public_el.pdf)

français (FR) (110.46 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/fr/documents/overview/duloxetine-zentiva-epar-summary-public_fr.pdf)

hrvatski (HR) (126.57 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/hr/documents/overview/duloxetine-zentiva-epar-summary-public_hr.pdf)

italiano (IT) (108.36 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/it/documents/overview/duloxetine-zentiva-epar-summary-public_it.pdf)

latviešu valoda (LV) (126.92 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/lv/documents/overview/duloxetine-zentiva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (128.35 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/lt/documents/overview/duloxetine-zentiva-epar-summary-public_lt.pdf)

magyar (HU) (126.95 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/hu/documents/overview/duloxetine-zentiva-epar-summary-public_hu.pdf)

Malti (MT) (130.99 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/mt/documents/overview/duloxetine-zentiva-epar-summary-public_mt.pdf)

Nederlands (NL) (109.73 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/nl/documents/overview/duloxetine-zentiva-epar-summary-public_nl.pdf)

polski (PL) (131.48 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/pl/documents/overview/duloxetine-zentiva-epar-summary-public_pl.pdf)

português (PT) (110.13 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/pt/documents/overview/duloxetine-zentiva-epar-summary-public_pt.pdf)

română (RO) (127.24 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/ro/documents/overview/duloxetine-zentiva-epar-summary-public_ro.pdf)

slovenčina (SK) (129.6 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/sk/documents/overview/duloxetine-zentiva-epar-summary-public_sk.pdf)

slovenščina (SL) (125.32 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/sl/documents/overview/duloxetine-zentiva-epar-summary-public_sl.pdf)

Suomi (FI) (108.74 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/fi/documents/overview/duloxetine-zentiva-epar-summary-public_fi.pdf)

svenska (SV) (109.03 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

27/08/2015

[View](/sv/documents/overview/duloxetine-zentiva-epar-summary-public_sv.pdf)

Duloxetine Zentiva : EPAR - Risk-management-plan summary

Reference Number: EMA/450483/2015

English (EN) (99.42 KB - PDF)

**First published:** 27/08/2015

**Last updated:** 27/08/2015

[View](/en/documents/rmp-summary/duloxetine-zentiva-epar-risk-management-plan-summary_en.pdf)

## Product information

Duloxetine Zentiva : EPAR - Product Information

English (EN) (353.45 KB - PDF)

**First published:** 27/08/2015

**Last updated:** 29/11/2024

[View](/en/documents/product-information/duloxetine-zentiva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-568)

български (BG) (453.57 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/bg/documents/product-information/duloxetine-zentiva-epar-product-information_bg.pdf)

español (ES) (445.84 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/es/documents/product-information/duloxetine-zentiva-epar-product-information_es.pdf)

čeština (CS) (397.79 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/cs/documents/product-information/duloxetine-zentiva-epar-product-information_cs.pdf)

dansk (DA) (495.71 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/da/documents/product-information/duloxetine-zentiva-epar-product-information_da.pdf)

Deutsch (DE) (237.38 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/de/documents/product-information/duloxetine-zentiva-epar-product-information_de.pdf)

eesti keel (ET) (511.2 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/et/documents/product-information/duloxetine-zentiva-epar-product-information_et.pdf)

ελληνικά (EL) (455.12 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/el/documents/product-information/duloxetine-zentiva-epar-product-information_el.pdf)

français (FR) (458.05 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/fr/documents/product-information/duloxetine-zentiva-epar-product-information_fr.pdf)

hrvatski (HR) (392.51 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/hr/documents/product-information/duloxetine-zentiva-epar-product-information_hr.pdf)

íslenska (IS) (379.5 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/is/documents/product-information/duloxetine-zentiva-epar-product-information_is.pdf)

italiano (IT) (273.22 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/it/documents/product-information/duloxetine-zentiva-epar-product-information_it.pdf)

latviešu valoda (LV) (415.91 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/lv/documents/product-information/duloxetine-zentiva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (978.89 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/lt/documents/product-information/duloxetine-zentiva-epar-product-information_lt.pdf)

magyar (HU) (420.23 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/hu/documents/product-information/duloxetine-zentiva-epar-product-information_hu.pdf)

Malti (MT) (450.5 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/mt/documents/product-information/duloxetine-zentiva-epar-product-information_mt.pdf)

Nederlands (NL) (441.48 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/nl/documents/product-information/duloxetine-zentiva-epar-product-information_nl.pdf)

norsk (NO) (370.72 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/no/documents/product-information/duloxetine-zentiva-epar-product-information_no.pdf)

polski (PL) (431.57 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/pl/documents/product-information/duloxetine-zentiva-epar-product-information_pl.pdf)

português (PT) (391.38 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/pt/documents/product-information/duloxetine-zentiva-epar-product-information_pt.pdf)

română (RO) (553.58 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/ro/documents/product-information/duloxetine-zentiva-epar-product-information_ro.pdf)

slovenčina (SK) (377.25 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/sk/documents/product-information/duloxetine-zentiva-epar-product-information_sk.pdf)

slovenščina (SL) (503.61 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/sl/documents/product-information/duloxetine-zentiva-epar-product-information_sl.pdf)

Suomi (FI) (382.97 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/fi/documents/product-information/duloxetine-zentiva-epar-product-information_fi.pdf)

svenska (SV) (375.55 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

29/11/2024

[View](/sv/documents/product-information/duloxetine-zentiva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMA/VR/0000226488 13/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Duloxetine Zentiva : EPAR - All Authorised presentations

English (EN) (15.97 KB - PDF)

**First published:** 27/08/2015

**Last updated:** 16/08/2022

[View](/en/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-963)

български (BG) (110.8 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/bg/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_bg.pdf)

español (ES) (53.42 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/es/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (73.72 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/cs/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (51.92 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/da/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.49 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/de/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (67.5 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/et/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (77.45 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/el/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_el.pdf)

français (FR) (70.2 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/fr/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (67.17 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/hr/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (67.24 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/is/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (33.52 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/it/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.28 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/lv/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (72.61 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/lt/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (74.4 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/hu/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (67.66 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/mt/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (35.9 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/nl/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.5 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/no/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_no.pdf)

polski (PL) (107.91 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/pl/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_pl.pdf)

português (PT) (68.95 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/pt/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_pt.pdf)

română (RO) (66.27 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/ro/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (71.21 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/sk/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (31.63 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/sl/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (64.36 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/fi/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (65.53 KB - PDF)

**First published:**

27/08/2015

**Last updated:**

16/08/2022

[View](/sv/documents/all-authorised-presentations/duloxetine-zentiva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Duloxetine Zentiva Active substance duloxetine International non-proprietary name (INN) or common name duloxetine Therapeutic area (MeSH)

- Neuralgia
- Depressive Disorder, Major
- Anxiety Disorders
- Diabetes Mellitus

Anatomical therapeutic chemical (ATC) code N06AX21

### Pharmacotherapeutic group

Other antidepressants

### Therapeutic indication

Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder.

Duloxetine Zentiva is indicated in adults.

## Authorisation details

EMA product number EMEA/H/C/003935

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Zentiva, k.s.

U kabelovny

Opinion adopted 25/06/2015 Marketing authorisation issued 20/08/2015 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Duloxetine Zentiva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (123.89 KB - PDF)

**First published:** 02/07/2024

**Last updated:** 29/11/2024

[View](/en/documents/procedural-steps-after/duloxetine-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Duloxetine Zentiva : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (163.65 KB - PDF)

**First published:** 02/12/2015

**Last updated:** 16/08/2022

[View](/en/documents/procedural-steps-after/duloxetine-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Duloxetine Zentiva : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/373461/2015

English (EN) (458.96 KB - PDF)

**First published:** 27/08/2015

**Last updated:** 27/08/2015

[View](/en/documents/assessment-report/duloxetine-zentiva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Duloxetine Zentiva

Adopted

Reference Number: EMA/CHMP/431635/2014

English (EN) (67.61 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 26/06/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-duloxetine-zentiva_en.pdf)

#### News on Duloxetine Zentiva

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2015) 26/06/2015

#### More information on Duloxetine Zentiva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/11/2024

## Share this page

[Back to top](#main-content)